Public Policy Letters, Statements, Legal Briefs, & Other Responses
-
ACMG Responds to FDA’s Approval for DTC Testing for Three BRCA Gene Mutations
-
Group Sign-on Letter to Congress (Senate) Opposing President’s Proposal to Eliminate Funding for HRSA’s Heritable Disorders Program
-
Group Sign-on Letter to Congress (House) Opposing President’s Proposal to Eliminate Funding for HRSA’s Heritable Disorders Program
-
ACMG/AMP/IDSA Joint Congressional Briefing on LDTs
-
ACMG-AMP Joint Webinar on Regulatory Oversite of LDTs (slides)
-
ACMG-AMP Joint Webinar on Regulatory Oversite of LDTs (recording)
-
ACMG Response to Expansion of Direct-to-Consumer Genetic Testing
-
ACMG Response to FDA’s Proposed Regulatory Framework for LDTs
-
ACMG One-Pager on FDA’s Proposed Regulatory Framework for LDTs
-
Group Sign-on Letter to Congress Urging Modernization of the Clinical Laboratory Improvement Amendments (CLIA)